HC Wainwright Issues Negative Outlook for KYMR Earnings

Key Points

• HC Wainwright cut its Kymera Therapeutics earnings forecasts, lowering its Q3 2026 EPS estimate to a loss of $1.04 from $0.69 and projecting continued losses through 2029. Its fiscal 2030 estimate was reduced to $0.22 per share, signaling a more cautious profitability outlook.
• Kymera’s latest quarterly results were better than expected: the company reported a $0.62 per-share loss versus the $0.71 consensus estimate, while revenue reached $65 million and surged 465.2% year over year.
• Despite the negative earnings revisions, analyst sentiment remains broadly positive, with 20 Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $125.65.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.04) for the quarter, down from their previous forecast of ($0.69). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($4.22) EPS, FY2028 earnings at ($4.32) EPS, FY2029 earnings at ($3.70) EPS and FY2030 earnings at $0.22 EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same quarter in the previous year, the business earned ($0.95) EPS. The firm's revenue for the quarter was up 465.2% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on KYMR. Oppenheimer restated an "outperform" rating and set a $125.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Truist Financial raised their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and upped their price target for the stock from $106.00 to $115.00 in a research note on Monday, July 13th. Finally, Barclays increased their price objective on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a report on Thursday. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $125.65.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $107.52 on Monday. The stock has a market cap of $8.94 billion, a price-to-earnings ratio of -33.19 and a beta of 1.95. Kymera Therapeutics has a 1 year low of $36.65 and a 1 year high of $130.05. The business has a fifty day moving average of $101.31 and a 200-day moving average of $88.93.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the sale, the director directly owned 240,123 shares of the company's stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 80,000 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,604,813 shares of company stock worth $387,557,004. Corporate insiders own 15.98% of the company's stock.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP grew its position in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock worth $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth $635,067,000.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera’s latest quarterly results provided support for the stock: the company reported a smaller-than-expected loss and revenue of $65 million, far above analyst expectations. Revenue increased 465% year over year, highlighting growing commercial and partnership-related momentum.
• Neutral Sentiment: Recent coverage describes conflicting analyst sentiment toward Kymera, suggesting that optimism over its therapeutic pipeline and growth prospects is being balanced by concerns about continued research-and-development spending and losses. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Kymera is drawing fresh investor attention, likely reflecting interest in its targeted protein degradation platform and pipeline. However, the available report does not identify a specific new clinical, regulatory, or partnership catalyst. Why Kymera Therapeutics Is Drawing Fresh Attention This Week?
• Negative Sentiment: Brookline Capital Markets lowered its third-quarter EPS estimate for Kymera, adding to concerns that near-term losses may be larger than previously expected. KYMR Q3 EPS Estimate Lowered by Brookline Capital Markets
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the third and fourth quarters of 2026 and for fiscal 2026 through 2029. Its fiscal 2030 estimate was also cut from $1.07 to $0.22 per share, signaling a more conservative view of Kymera’s path to profitability.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source